Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2008

View Archived Issues

Improved in vitro profile and therapeutic index with Pfizer's new bronchodilator UK-503590

Targeting the GPR4 receptor shows benefit in models of lung injury and COPD

Johnson & Johnson new LTA4H inhibitor reduces allergic airways inflammation in vivo

ST-2472 exhbits potent antipsychotic effects and good safety profile in vivo

Antitumor effects of chemotherapy enhanced by inhibition of N-cadherin

Novel mechanism for benzodiazepine receptor ligand PK-11195 identified

Medivir reports new therapeutic options for HCV infection in recent patent

Recent patents describe novel treatment alternatives for eye disorders

Recent patents disclose novel anti-HIV agents

Recent patents impart novel treatment options for cancer

DOR BioPharma withdraws E.U. MAA for orBec and plans phase III study

Allon completes dosing in phase II AL-208 cognitive impairment trial

FDA issues approvable letter for bazedoxifene in postmenopausal osteoporosis

GTx phase III toremifene trial continues after interim efficacy analysis

Novo Nordisk files for regulatory approval of liraglutide in the U.S. and Europe

ProStrakan grants exclusive license to JapanBridge for Sancuso in parts of Asia

Panobinostat active against poorly differentiated and anaplastic thyroid carcinoma cells

First patients enrolled in switch trial of oral iclaprim

Synthetic Blood International obtains exclusive license to VCU discoveries

Draxis Health acquisition approved by shareholders

First MS therapeutic from Novartis approved for launch in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...